Cover Image
市場調查報告書

非洲昏睡病(African trypanosomiasis非洲錐蟲病):開發中產品分析

African Trypanosomiasis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 265423
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
非洲昏睡病(African trypanosomiasis非洲錐蟲病):開發中產品分析 African Trypanosomiasis - Pipeline Review, H1 2017
出版日期: 2017年03月22日 內容資訊: 英文 46 Pages
簡介

非洲昏睡病又名非洲錐蟲病,是由於寄生蟲布氏椎蟲寄生而感染,透過舌蠅的刺咬傳播給人類。症狀有不安感、整天嗜睡、發燒、頭痛、失眠、心情變化、嗜睡(無法控制的情況)、盜汗、身體淋巴節腫脹、虰咬部分腫起、皮膚發紅、會疼痛的結痂化、肌肉無力等,治療方法有使用抗原蟲藥等。

本報告網羅全球非洲昏睡症治療藥的開發平台資訊,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

非洲昏睡病概要

治療藥的開發

  • 非洲昏睡病轉動開發中產品:概要
  • 非洲昏睡病轉動開發中產品:比較分析

非洲昏睡病:開發中的治療藥:各企業

非洲昏睡病:開發中的治療藥:各大學·研究機關

非洲昏睡病:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

非洲昏睡病:開發中的產品:各企業

非洲昏睡病:開發中的產品:各大學·研究機關

非洲昏睡病:治療藥的開發企業

  • Anacor Pharmaceuticals, Inc.
  • Sanofi
  • Scynexis, Inc

非洲昏睡病:治療藥的評估

  • 單劑治療藥
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

最新的開發平台趨勢

暫停中的計劃

中止開發的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9086IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide African Trypanosomiasis - Pipeline Review, H1 2017, provides an overview of the African Trypanosomiasis (Infectious Disease) pipeline landscape.

African trypanosomiasis (also known as African sleeping sickness) is a parasitic infection caused by a species of parasite, Trypanosoma brucei, which is transmitted to humans through the bite of the tsetse fly. Symptoms include anxiety, drowsiness during the day, fever, headache, insomnia at night, mood changes, sleepiness (may be uncontrollable), sweating, swollen lymph nodes all over the body, swollen, red, painful nodule at site of fly bite and weakness. Treatment includes anti-protozoal agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide African Trypanosomiasis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for African Trypanosomiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The African Trypanosomiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 3 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 3 molecules, respectively.

African Trypanosomiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of African Trypanosomiasis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for African Trypanosomiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in African Trypanosomiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates African Trypanosomiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for African Trypanosomiasis (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for African Trypanosomiasis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding African Trypanosomiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • African Trypanosomiasis - Overview
  • African Trypanosomiasis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • African Trypanosomiasis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • African Trypanosomiasis - Companies Involved in Therapeutics Development
  • Incuron LLC
  • Novartis AG
  • Sanofi
  • Scynexis Inc
  • African Trypanosomiasis - Drug Profiles
  • AN-5568 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CBL-0137 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DDD-100097 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fexinidazole - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GNF-6702 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • melarsoprol hydroxypropylbetadex - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MS-08 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptides for Sleeping Sickness - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for African Trypanosomiasis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Infectious Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Sleeping Sickness - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease, Leishmaniasis and African Trypanosomiasis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Leucyl-tRNA Synthetase (LeuRS) for Human African Trypanosomiasis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit N-Myristoyltransferase for African Trypanosomiasis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Variant Surface Glycoprotein for African Trypanosomiasis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • African Trypanosomiasis - Dormant Projects
  • African Trypanosomiasis - Discontinued Products
  • African Trypanosomiasis - Product Development Milestones
  • Featured News & Press Releases
  • Aug 30, 2016: UGA researchers discover a drug for a tropical disease
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for African Trypanosomiasis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • African Trypanosomiasis - Pipeline by Incuron LLC, H1 2017
  • African Trypanosomiasis - Pipeline by Novartis AG, H1 2017
  • African Trypanosomiasis - Pipeline by Sanofi, H1 2017
  • African Trypanosomiasis - Pipeline by Scynexis Inc, H1 2017
  • African Trypanosomiasis - Dormant Projects, H1 2017
  • African Trypanosomiasis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for African Trypanosomiasis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top